In one paragraphArticle in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Fernando Valdivieso-RiveraObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0001-5044-197X Vanessa O FurinoObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Carlos E LeherObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0001-6517-8334 Ariane M ZanescoObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0003-4842-1421 Monara Kaélle CruzLaboratory of Immunometabolism, Department of Genetics, Evolution, Microbiology and Immunology-Institute of Biology, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Flavia C GanObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Adriana Leandra SantoroObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0002-7208-5037 Lara Regina-FerreiraObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Giovanna Leite SantosDepartment of Pathology, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Tiago GonçalvesCenter for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, Brazil.
Luiz Osório LeiriaCenter for Research in Inflammatory Diseases (CRID), Ribeirão Preto Medical School, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, Brazil.ORCID 0000-0001-9483-3705 Pedro M Moraes-VieiraObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.
Roger Frigério CastilhoDepartment of Pathology, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0003-2338-8717 Shingo KajimuraDivision of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, USA.ORCID 0000-0003-0672-5910 Marcelo A MoriObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0001-7112-5263 Licio A VellosoObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil.ORCID 0000-0002-4806-7218 Carlos H SpontonObesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, Brazil. csponton@usp.br.ORCID 0000-0003-4284-8176 Funding
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) 2019/15025-5,2020/14725-0,2020/06057-8,2021/08354-2,2013/07607-8,2021/12964-0
6 · The paper itselfAbstract
Brown adipose tissue (BAT) counteracts obesity-related metabolic dysfunction through both thermogenic and non-thermogenic means. However, substantial evidence indicates that obesity negatively affects BAT mitochondrial morphology and oxidative capacity, impairing systemic energy homeostasis. Motivated by this apparent contradiction, we investigate the relationship between obesity and mitochondrial dynamics, as the underlying mechanisms remain incompletely understood. Here, we identify E4BP4 as a transcriptional repressor that prevents obesity-induced mitochondrial fragmentation and oxidative dysfunction by inhibiting ceramide synthesis in brown fat. Specifically, E4BP4 interacts with PRDM16 to repress Cers6 mRNA expression and consequently reduces C16:0 ceramide levels by binding to a 65 kb upstream enhancer region of the Cers6 gene. Notably, the preservation of mitochondrial integrity in BAT by E4BP4 gain-of-function improves systemic glucose homeostasis, independent of weight loss. Collectively, our findings establish E4BP4 as a molecular safeguard against obesity-induced mitochondrial fragmentation and oxidative dysfunction, primarily by suppressing ceramide synthesis in brown fat.
Indexed as
Adipose Tissue, BrownCeramidesMitochondriaObesityAnimalsDNA-Binding ProteinsGene Expression RegulationHumansMiceProtein BindingSphingosine N-AcyltransferaseTranscription FactorsCeramidesDNA-Binding ProteinsPrdm16 protein, mouseSphingosine N-AcyltransferaseTranscription Factors
Identifiers
PMID42332066
PMCPMC13458363
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390